We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Coziana
Ciurtin
c.ciurtin@ucl.ac.uk
Prof
Francesco
D'Aiuto
f.daiuto@ucl.ac.uk
Diseases of oral cavity, salivary glands and jawsSystemic connective tissue disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Many studies have conducted to evaluate the relationship of systemic inflammatory diseases with periodontal disease. Previous evaluations suggest that there is no significant association between patients with SLE and PD. However, some of the studies have shown relevancy between these two inflammatory diseases and have suggested to explore more for further knowledge. The aim of the study is to establish and investigate a relationship between SLE and Periodontitis. The study which will take place in one centre and will recruit 30 patients which will enter a pilot randomized controlled trial. Individuals enrolled into the study will be randomly assigned to the test or control group in a 1:1 ratio. Study will be divided in to six visits for the patients and the length of the study will be of 6 months. Visit 1 will be consisting of Screening including consent and Periodontal examination of the patients. Visit 2 includes OPg, Comprehensive periodontal examination recording, Blood samples collection vascular function assessment and OCT. Intensive periodontal treatment (IPT) for test group and control periodontal treatment (CPT) for control group including medical history recording according to group allocation in visit 3 for control group and (3a and 3b) for test group will take place. Follow ups after two months will be conducted in Visit 4 for both groups including Demographics, medical history and concomitant medications recording, comprehensive periodontal examination recording, OCT, blood samples/saliva samples collection and vascular function assessment. Visit 3 and 5 will be conducted as periodontal treatment (IPT for test group and CPT for the control group), medical history recording, including demographics, QRISK3 questionnaire (Visit 2 and visit only) to assess the cardio-vascular risk medical history and concomitant medications recording, comprehensive periodontal examination recording, blood samples collection and vascular function assessment. Last visit will be 6 months follow up.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Other;
You can take part if:
You may not be able to take part if:
Subjects meeting any of the following exclusion criteria are not to be enrolled: Male and Female that are: 1. Pregnancy or breastfeeding. 2. Having fewer than 15 teeth. 3. Subject knowingly has HIV or Hepatitis. 4. Subject is not capable to give informed consent. 5. Presence of concomitant rheumatoid arthritis, Sjogren syndrome, diabetes mellitus. 6. Smoking. 7. Subject on anticoagulants. 8. Subjects on chronic antibiotic therapy or who require antibiotic coverage for periodontal procedures. 9. Subjects who received periodontal treatment within 6 months from the baseline
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University College London and funded by VERSUS ARTHRITIS .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 44210
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
